|
By U.S. District Judge Shkreli drew notoriety in 2015 after hiking Daraprim's price overnight to In a 130-page decision, Cote faulted Shkreli for creating two companies, Vyera and Retrophin Inc, designed to monopolize drugs so he could profit "on the backs" of patients, doctors and distributors. She said the Daraprim scheme was "particularly heartless and coercive," and a lifetime industry ban was needed because of the "real danger" that Shkreli could become a repeat offender. "Shkreli's anticompetitive conduct at the expense of the public health was flagrant and reckless," the judge wrote. "He is unrepentant. Barring him from the opportunity to repeat that conduct is nothing if not in the interest of justice." After the ruling, FTC Chair Shkreli's lawyers did not immediately respond to a request for comment. Shkreli is serving a seven-year prison sentence for securities fraud. He did not attend the trial held last month. Vyera was founded in 2014 as Turing Pharmaceuticals, and acquired Daraprim from Impax Laboratories Inc in 2015. Regulators accused Vyera of protecting its dominance of Daraprim by ensuring that generic drugmakers could not obtain samples for cheaper versions, and keeping potential rivals from buying a key ingredient. The seven states joining the FTC case included (Reporting by
Copyright © Reuters 2008.
All rights reserved. Republication or redistribution of Reuters content,
including by caching, framing or similar means, is expressly prohibited without
the prior written consent of Reuters. Reuters and the Reuters sphere logo are
registered trademarks and trademarks of the Reuters group of companies
around the world.
Search NewsFilter ResultsPublication DateTopic
Provider |
News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.